Role of toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated interleukin 8 responses in neutrophils by Kurt-Jones, Evelyn A. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2002-08-15 
Role of toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF 
enhances TLR2 expression and TLR2-mediated interleukin 8 
responses in neutrophils 
Evelyn A. Kurt-Jones 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Biological Phenomena, Cell Phenomena, and Immunity Commons, Cell and Developmental 
Biology Commons, Hematology Commons, Microbiology Commons, and the Pediatrics Commons 
Repository Citation 
Kurt-Jones EA, Mandell L, Whitney C, Padgett A, Gosselin K, Newburger PE, Finberg RW. (2002). Role of 
toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated 
interleukin 8 responses in neutrophils. Open Access Articles. Retrieved from 
https://escholarship.umassmed.edu/oapubs/281 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
2002 100: 1860-1868
 
 
 
 
 
Newburger and Robert W. Finberg 
Evelyn A. Kurt-Jones, Leisa Mandell, Constance Whitney, Alison Padgett, Kerri Gosselin, Peter E.
 
 neutrophils
enhances TLR2 expression and TLR2-mediated interleukin 8 responses in 
Role of Toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF
 http://bloodjournal.hematologylibrary.org/cgi/content/full/100/5/1860
Updated information and services can be found at: 
 (944 articles)Phagocytes 
 collections: BloodArticles on similar topics may be found in the following 
 http://bloodjournal.hematologylibrary.org/misc/rights.dtl#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at: 
 http://bloodjournal.hematologylibrary.org/misc/rights.dtl#reprints
Information about ordering reprints may be found online at: 
 http://bloodjournal.hematologylibrary.org/subscriptions/index.dtl
Information about subscriptions and ASH membership may be found online at: 
. Hematology; all rights reservedCopyright 2007 by The American Society of 
DC 20036.
by the American Society of Hematology, 1900 M St, NW, Suite 200, Washington 
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published semimonthly
 
 
 
 
 For personal use only. at UNIV OF MASSACHUSETTS on April 3, 2008. www.bloodjournal.orgFrom 
PHAGOCYTES
Role of Toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances
TLR2 expression and TLR2-mediated interleukin 8 responses in neutrophils
Evelyn A. Kurt-Jones, Leisa Mandell, Constance Whitney, Alison Padgett, Kerri Gosselin, Peter E. Newburger, and Robert W. Finberg
In vitro studies as well as clinical trials
indicate that the cytokines granulocyte-
macrophage colony-stimulating factor
(GM-CSF) and granulocyte colony-
stimulating factor (G-CSF) enhance the
ability of neutrophils (polymorpho-
nuclear leukocytes) to eliminate micro-
bial organisms. Toll-like receptor (TLR)
proteins, homologs of the Drosophila
protein Toll, have been found on the
surface of mammalian cells and are
important in the responses of macro-
phages to bacterial, viral, and fungal
antigens. TLR4 is critical for the re-
sponse to lipopolysaccharide (LPS) of
gram-negative bacteria, while TLR2 is
important for response to gram-positive
bacteria, bacterial peptides, and yeast
zymosan. We demonstrate that TLR2,
but very little TLR4, is present on the
surface of human neutrophils. In addi-
tion we demonstrate that GM-CSF and
G-CSF dramatically up-regulate TLR2
and CD14 surface expression. GM-CSF
treatment also up-regulates TLR2 and
CD14 mRNA levels in neutrophils. In
addition to increasing receptor expres-
sion, GM-CSF treatment enhanced the
interleukin 8 (IL-8) secretion and super-
oxide priming responses of neutrophils
to stimulation with TLR2 ligands, includ-
ing zymosan, peptidoglycan, and li-
poarabinomannan. The human mono-
cyte response to crude bacterial LPS is
composed of a TLR4-specific response
to the pure LPS component and a TLR2-
dependent response to associated li-
popeptides. The removal of TLR2 li-
popeptide components from LPS by
phenol re-extraction substantially re-
duced both the IL-8 and superoxide
response of the stimulated neutrophils,
indicating that, unlike monocytes, the
neutrophil response is preferentially di-
rected to TLR2 ligands. Thus, our stud-
ies demonstrate that GM-CSF dramati-
cally enhances the functional response
of neutrophils to TLR2 ligands, includ-
ing LPS-associated lipopeptides. (Blood.
2002;100:1860-1868)
© 2002 by The American Society of Hematology
Introduction
Neutrophils provide the rapid deployment and effector arm of the
innate immune system. Approximately 1011 per day transit through
the human circulation en route to tissue, where they form the first
line of cellular defense against invading microorganisms.1,2 As
potent agents of the inflammatory response, they also play a major
role in the inflammation and tissue damage of a wide variety of
noninfectious diseases, such as arthritis, inflammatory bowel
disease, and ischemia-reperfusion injury.3-5
These motile, phagocytic cells respond to a wide variety of
particulate and soluble stimuli.6,7 Exposure to other agents, most of
which do not activate neutrophils directly, elicits a priming reaction
that enhances subsequent function in response to other activating
stimuli or to higher doses of the priming agent.8 Priming stimuli
include bacterial lipopolysaccharide (LPS), cytokines such as
granulocyte-macrophage colony-stimulating factor (GM-CSF), and
low doses of chemotactic molecules such as formylated peptides,
including f-Met-Leu-Phe (f-MLP) and C5a.8-10 Primed neutrophils
exhibit enhanced expression of integrins and selectins, inhibition of
apoptosis, and membrane assembly of the nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase complex.8,10,11
Many functionally important receptors for microbial ligands on
neutrophils have not yet been identified. Recently, a family of
receptor proteins, the Toll-like receptors (TLRs), has been identi-
fied in mammals.12-14 TLRs mediate cellular responses to a large
array of microbial ligands. At present, 10 different TLR proteins
have been cloned.15,16 TLR2 is the receptor for a variety of
microbial ligands, including gram-positive bacteria, peptidoglycan,
yeast zymosan, and mycobacterial ara-lipoarabinomannan
(araLAM).15,16 TLR4 is a receptor for gram-negative bacteria, LPS,
and some viruses.15-17 TLR4 and TLR2, like other TLR family
members, have a conserved intracellular signaling motif. This
signaling motif, which is also found in the intracellular domain of
the IL-1 receptor (IL-1R), is responsible for nuclear factor-B
(NF-B) activation/translocation after TLR or IL-1R receptor
engagement and is an essential signaling pathway for IL-1 and
tumor necrosis factor- (TNF-) secretion.18 RNA transcripts
encoding TLR family members TLR2 and TLR4 have been
detected in human peripheral blood neutrophils.19
A second important receptor for microbial ligands is CD14.
CD14 is a glycosylphosphatidylinositol (GPI)–anchored protein
expressed at high levels on the surface of circulating monocytes.20
CD14 has also been detected in neutrophils, where it primarily
resides within granules.21-23 A soluble form of CD14 is present in
serum; membrane and soluble CD14 function as coreceptors for
microbial ligands, including LPS, zymosan, peptiodoglycan, and
araLAM.24 In this paper, we examine the role of TLR2, TLR4, and
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CD14 protein expression and receptor function in human periph-
eral blood neutrophils and demonstrate a functional role for TLR2
in neutrophil responses to microbial ligands.
We demonstrate that (1) TLR2 and CD14 are expressed on the
surface of neutrophils as well as on the surface of monocytes; (2)
cell surface expression of both TLR2 and CD14 on neutrophils is
modulated by external factors, TLR2 and CD14 expression being
up-regulated by GM-CSF, LPS, and G-CSF, while only minimal
effects on monocyte receptor expression are seen; and (3) the
neutrophil response to bacterial and yeast cell wall components is
enhanced by GM-CSF, while this cytokine has minimal effects on
the monocyte responses to the same stimuli.
Materials and methods
Cell culture and reagents
Human embryonic kidney HEK293 cells (ATCC, Rockville, MD) were
grown in RPMI-1640 medium (Gibco BRL, Grand Island, NY) supple-
mented with 10% heat-inactivated fetal bovine serum (Atlanta Biologicals,
Norcross, GA). LPS from Escherichia coli serotype 0111:B4, f-Met-Leu-
Phe, and zymosan were purchased from Sigma (St Louis, MO). Zymosan
preparations consisted of yeast cell walls (ghost cells) with an average
particle diameter of 3 microns. Peptidoglycan was obtained from ICN
(Costa Mesa, CA). AraLAM was provided by Dr John Belisle (Fort Collins,
CO) under National Institute of Allergy and Infectious Diseases (NIAID)
contract NO1-AI-75320 entitled “Tuberculosis Research Materials and
Vaccine Testing.” Phenol extraction of the commercial (stock) preparation
of LPS was performed as described by Manthey et al.25 GM-CSF (Leukine)
was obtained from Immunex (Seattle, WA), and G-CSF (Neupogen) was
obtained from Amgen (Thousand Oaks, CA).
Isolation and staining of neutrophils and peripheral blood
mononuclear cells
Neutrophils were isolated from normal human peripheral blood by dextran
sedimentation and centrifugation through Ficoll-Hypaque (Amersham
Biosciences, Piscataway, NJ). Neutrophils were recovered from the pellet
and mononuclear cells were recovered from the interface, as previously
described,26 using a protocol that minimizes activation of the neutrophils
during isolation. Cells were cultured in RPMI-1640 supplemented with
10% fetal calf serum and antibiotics. Cells were cultured in 24-well culture
dishes at a density of 107 per well (neutrophils) or 106 per well
(mononuclear cells). Culture supernatants were collected 18 hours after
stimulation, and IL-8 levels were determined by enzyme-linked immunosor-
bent assay (ELISA) (Pierce-Endogen, Rockford, IL). All reagents, serum,
buffers, and media were free of LPS ( 0.01 ng/mL by Limulus
amoebocyte lysate assay, Sigma). For fluorescence-activated cell-sorter
scanner (FACS) staining, neutrophils and monocytes were incubated with
the minimal priming doses of LPS, which were determined to be 0.25
ng/mL for neutrophils and 1 ng/mL LPS for monocytes, based on pilot
dose-response experiments. In all other analyses, both neutrophils and
monocytes were incubated with a maximal activating dose of 10 ng/mL LPS.
CD14, TLR2, and TLR4 receptor expression were determined by flow
cytometry. Cells were stained with anti-CD14 mAb (clone MY4; Coulter
Immunology, Hialeah, FL), anti-TLR2 (clone TL2.1; gift of Dr Espevik,
Trodheim, Norway), anti-TLR4 (clone HTA125; eBiosciences, San Diego,
CA), or isotype control antibodies (Sigma). Antibody binding was detected
using a phycoerythrin (PE)–labeled goat anti–mouse IgG antiserum (Sigma).
In some experiments, directly PE-labeled anti-TLR2 (TL2.1) and anti-
TLR4 (HTA125) antibodies purchased from eBiosciences were used. Cells
were fixed in RBC Lysing Solution (Becton-Dickinson, San Jose, CA) and
analyzed using a FACScan analyzer. For each time point and assay
condition, at least 10 000 cells were analyzed. Statistical analysis was
performed by the Kolmogorov-Smirnoff algorithm analysis and by Probabil-
ity Binning Chi(T) analysis using FlowJo software for univariant analysis
of population distributions of FACS data (Tree Star, San Carlos, CA). For
Probability Binning Chi(T) analysis, a minimum value of ChiT(X)  100
for comparison of 2 populations was applied for significance at the
P  .001 level. For Kolmogorov-Smirnoff analysis, a minimum of 30%
positive events in samples compared to controls by Super-enhanced Dmax
Subtraction at the P  .001 level for each comparison of 2 populations
was applied (Tree Star, San Carlos, CA).
Generation of stable TLR- and CD14-expressing clones
HEK293 cells were transfected with plasmids encoding puromycin resis-
tance (gift of Dr Richard Kitchens, University of Texas Southwestern
Medical Center), human TLR2 or TLR4 (Tularik, San Francisco, CA;
FLAG-epitope tagged at the N-terminus), and/or human CD14 using Escort
reagent (Sigma) according to manufacturer’s protocol. Forty-eight hours
later, 5 g/mL puromycin was added to the cultures. Clones of puromycin-
resistant cells were isolated and analyzed by FACS for surface expression of
proteins, using anti-FLAG mAb to detect TLR proteins and anti-CD14 mAb
followed by a PE-labeled goat anti–mouse IgG (Sigma). Clones expressing
equivalent levels of TLR proteins were selected for further study. Cells
were plated in 24-well culture dishes, and 24 hours later the medium was
replaced with fresh medium containing LPS or no stimulant. After 18 hours
of stimulation, culture supernatants were harvested, and IL-8 levels in the
supernatants were measured using a commercial IL-8 ELISA assay
kit (Endogen).
Northern blot analysis
Neutrophils were incubated with or without GM-CSF (10-100 U/mL) for 2
hours. RNA was extracted by the guanidine HCl method.26 RNA from
control transfected cell lines was similarly extracted. Northern blot analysis
was performed according to standard procedures,27 using 32P-labeled
cDNAs for the human TLR2 and CD14 genes as hybridization probes.
Sequential cycles of filter stripping and reprobing were performed as
previously described.28 Equal loading of lanes was demonstrated by
examination of gels after ethidium-bromide staining and by rehybridization
with a 5.8-kilobase HindIII restriction fragment of rat 18S ribo-
somal cDNA.29
Superoxide release
Superoxide release was measured by a modified superoxide dismutase
(SOD) inhibitable cytochrome c reduction assay.30 Neutrophils (8  105
per tube) were incubated for 90 minutes in Hanks balanced salt solution
(HBSS) without phenol red, with or without GM-CSF 10 U/mL, then
further incubated 30 minutes at 37°C with no stimulus or with one of the
following TLR ligands: zymosan (1 g/mL), araLAM (1 g/mL), pepti-
doglycan (1 g/mL), commercial (stock) LPS (10 ng/mL), or phenol-
extracted LPS (10 ng/mL). Superoxide generation was then measured by
the addition of cytochrome c (50 M) and formyl-methionyl-leucyl-
phenylalanine (f-MLP, 107 M) in the presence of dihydrocytochalasin B
(10-5 M). One reference tube for each experimental group also received
SOD (60 U/mL). After 15 minutes of incubation at 37°C, the reaction was
stopped by placing the tubes on ice and the cells removed by centrifugation
for 1 minute at 15 000g. The light absorbance of the supernatants was
measured at 550 nm, and the amount of superoxide released was calculated
from the difference in A550 between the assay and SOD-containing tubes,
using an extinction coefficient of 0.21 nM1 cm1. The results are
expressed as nmol of superoxide released per minute per 106 cells.
Results
Neutrophils express TLR2 and CD14
We examined the expression of the Toll-like receptors TLR2 and
TLR4, as well as CD14, on normal human peripheral blood
neutrophils and compared neutrophil receptor expression to the
expression of these receptors on monocytes. TLR2 and CD14 were
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expressed at moderate levels on neutrophils. The levels of TLR2
and CD14 expressed on monocytes were higher than the levels of
these receptors expressed on neutrophils from the same donor
(Figure 1). TLR4 was only weakly expressed on freshly isolated
neutrophils (Figure 1) and was undetectable on neutrophils cul-
tured in medium for 2 hours (data not shown; and Figure 2). In
contrast, we readily detected TLR4 expression on monocytes
isolated at the same time from the same donor (Figure 1), even after
culturing the cells in medium (data not shown). This pattern of low
TLR2 and CD14 expression and weak or undetectable TLR4
expression on neutrophils compared to levels of the same proteins
on monocytes was observed with all of the donors we examined.
(n  7 donors tested on 14 separate occasions. Concurrent flow
cytometric analysis of neutrophils and monocytes from individual
donors is shown in Figures 1 and 5.)
GM-CSF increases TLR2 and CD14 expression on neutrophils
GM-CSF has been shown to prime neutrophils for responses to
LPS.31,32 Therefore, we examined the effect of GM-CSF treatment
on neutrophil expression of TLR2, TLR4, and CD14. Neutrophils
were isolated from peripheral blood and incubated with 100 U/mL
GM-CSF for 2 hours. GM-CSF treatment increased TLR2 and
CD14 expression on neutrophils (Figure 2) but did not affect TLR4
expression. In contrast, GM-CSF had little effect on TLR2, TLR4,
or CD14 expression on monocytes (data not shown).
Kinetic analysis indicated that GM-CSF enhancement of TLR2
and CD14 expression on neutrophils was detectable within 1 hour
of GM-CSF treatment and was maintained over a 3-hour period
(Figure 3). Class I major histocompatibility complex (MHC)
expression was unaffected by GM-CSF treatment. Neutrophils
incubated without GM-CSF had stable expression of TLR2 over
the first 2 hours, although CD14 expression declined slightly at the
2-hour time point. At 3 hours of incubation, expression of all 3
Figure 1. Expression of Toll-like receptors and CD14 on neutrophils and
monocytes. Expression of TLR2, TLR4, and CD14 on peripheral blood neutrophils
and monocytes was measured by fluorescence analysis of cells stained with
anti-TLR2, anti-TLR4, anti-CD14, or isotype-control mAbs followed by PE-labeled
goat anti–mouse Ig Ab. Isotype-control Ab–stained cells are shown as gray histo-
grams. Specific mAb–stained cells are shown as black line histograms. Geometric
mean fluorescence intensity (SD). Neutrophils: isotype control, 4.7 (0.3); TLR2, 22.6
(0.5); TLR4, 6.3 (0.3); and CD14, 42.1 (0.5). Monocytes: isotype control, 6.3 (0.3);
TLR2, 96.6 (0.3); TLR4, 23.4 (0.2); and CD14, 1183 (0.3).
Figure 2. GM-CSF and G-CSF enhance TLR2 and CD14 expression on neutrophils. Neutrophils were incubated with GM-CSF (100 U/mL), G-CSF (100 U/mL), or medium
alone for 2 hours prior to staining and FACS analysis. Isotype-control Ab–stained cells are shown as gray histograms. Specific mAb–stained cells are shown as black line
histograms. Geometric mean fluorescence intensity (SD). Neutrophils treated with medium alone: isotype control, 7.9 (0.4); TLR2, 12.3 (0.3); TLR4, 8.5 (0.3); and CD14, 17.5
(0.3). Neutrophils treated with GM-CSF: isotype control, 7.9 (0.4); TLR2, 19.4 (0.4); TLR4, 9.2 (0.4); and CD14, 33.8 (0.4). Neutrophils treated with G-CSF: isotype control, 7.9
(0.4); TLR2, 18.0 (0.4); TLR4, 8.8 (0.3); and CD14, 24.7 (0.4). Significance of difference between treated cells and untreated controls: **P  .001 by Probability Binning ChiT
analysis (ChiT(X)	 450); P  .001 by Kolmogorov-Smirnoff analysis.
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surface receptors (Class I MHC, TLR2, and CD14) was reduced.
Nevertheless, GM-CSF–treated neutrophils maintained higher lev-
els of TLR2 and CD14 than medium-treated cells, even at 3 hours
(Figure 3).
Northern blot analysis demonstrated that neutrophils have low
or undetectable levels of TLR2 and CD14 mRNA when isolated
from peripheral blood (Figure 4). Both TLR2 and CD14 mRNA
levels increased after treatment with GM-CSF (Figure 4), suggest-
ing that the increase in TLR2 and CD14 expression observed by
flow cytometry was due to increased gene transcription. TLR4
mRNA was not detected in either untreated or GM-CSF–treated
neutrophils, consistent with the lack of TLR4 protein detectable by
flow cytometry of these cells (data not shown; and Figures 1, 2,
and 5).
G-CSF increases TLR2 and CD14 expression on neutrophils
G-CSF, like GM-CSF, has been shown to prime neutrophils for
responses to LPS.8,31,32 Therefore, we examined the effect of
G-CSF treatment on neutrophil receptor expression. G-CSF in-
creased TLR2 and CD14 expression on neutrophils (Figure 2).
TLR4 remained low or undetectable on treated neutrophils (Figure
2). These results suggest that neutrophil priming by GM-CSF and
G-CSF may be due, at least in part, to increased TLR2 and CD14
receptor expression.
LPS increases TLR2 and CD14 expression on neutrophils
and down-regulates TLR4 expression on monocytes
TLR4 expression is known to be regulated by LPS.19,33,34 We
examined the effect of LPS treatment on TLR2, TLR4, and CD14
receptor expression on neutrophils and mononuclear cells incu-
bated with LPS for 2 hours (Figure 5). LPS increased TLR2
expression on neutrophils and, to a lesser degree, on monocytes.
CD14 expression on neutrophils was also increased by LPS
treatment (Figure 5). In contrast, LPS treatment down-regulated
TLR4 expression on monocytes. Neutrophils had low or undetect-
able TLR4 expression both before and after LPS treatment
(Figure 5).
GM-CSF enhances neutrophil responses to TLR2 ligands
TLR2 is an essential receptor for cellular responses to gram-
positive bacteria, mycobacteria, and yeast.16,35,36 Transfection stud-
ies of human and rodent cells and studies of TLR2 knockout mice
have identified several microbial components that activate host-cell
responses via TLR2 (and CD14). These include peptidoglycan, a
cell wall component of gram-positive bacteria; zymosan, a cell wall
component of yeast; and araLAM, a component of Mycobacterium
tuberculosis.16,35,36
Our experiments showed that GM-CSF enhanced neutrophil
expression of TLR2 (Figures 2-4). This prompted us to examine the
effect of GM-CSF treatment on neutrophil responses to TLR2
ligands. Neutrophils, isolated from peripheral blood, were treated
with increasing doses of GM-CSF and stimulated with peptidogly-
can, zymosan, or araLAM (Figures 6-8). GM-CSF treatment
induced a dose-dependent increase in the IL-8 response of neutro-
phils to peptidoglycan (Figure 6), zymosan (Figure 7), and
araLAM (Figure 8), suggesting that increased TLR2 expression
after GM-CSF treatment may enhance neutrophil responsiveness to
TLR2 ligands. The receptor specificity of each of these ligands was
analyzed by stimulating TLR- (and CD14) expressing HEK293
transfected cell lines and measuring IL-8 secretion. Peptidoglycan,
zymosan, and araLAM each stimulated transfected cell lines in a
TLR2-dependent manner (Figures 6-8, panel B).
Monocytes constitutively express higher levels of TLR2 than
neutrophils (Figures 1 and 5). Consistent with their higher levels of
TLR2 (and CD14) expression, monocytes are activated by the
TLR2 ligands, peptidoglycan (Figure 6), and zymosan (Figure 7) at
near optimal levels, even in the absence of GM-CSF treatment. In
contrast to its effect on monocyte responses to zymosan and
peptidoglycan, GM-CSF treatment enhanced the response of
monocytes, as well as neutrophils, to araLAM (Figure 8). These
results suggest that in addition to TLR2, GM-CSF may increase
expression of an araLAM-specific receptor, perhaps a TLR in-
volved in heterodimer formation with TLR2.
Figure 4. GM-CSF increases TLR2 and CD14 mRNA levels in neutrophils.
Neutrophils were incubated with GM-CSF (10-100 U/mL) or medium alone for 2
hours, and mRNA was extracted for Northern blot analysis. Positive control mRNA
was extracted from Chinese hamster ovary (CHO) cells stably transfected with
human CD14 alone or CD14 in combination with human TLR2. Samples, each
containing 10 g RNA, were electrophoresed and blotted on nylon-nitrocellulose
membranes. (Equal loading was confirmed by ethidium-bromide staining and
hybridization of the blots with an 18S ribosomal cDNA probe.) Northern blots were
probed with labeled human TLR2 (upper blot), CD14 (lower blot), and TLR4 (not
shown) cDNAs.
Figure 3. Kinetics of GM-CSF–induced TLR2 and CD14 expression. Neutrophils
were incubated with GM-CSF (100 U/mL) or medium alone for up to 3 hours at 37°C.
At the indicated times, cells were stained and analyzed for expression of TLR2,
CD14, and Class I MHC. Data are expressed as geometric mean fluorescence
intensity of cells stained at t  0 (immediately after isolation) or following incubation
for 1, 2, or 3 hours prior to staining. Significance of difference between treated cells
and untreated controls: **P  .001 by Probability Binning ChiT analysis (ChiT(X) 	
330); P  .001 by Kolmogorov-Smirnoff analysis.
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GM-CSF enhances neutrophil responses to the TLR2-activating
component of commercial LPS
Genetic studies have shown that LPS-induced activation is depen-
dent on TLR4 and CD14 expression.37-40 While many studies have
demonstrated neutrophil responses to LPS, our experiments indi-
cate that neutrophils express low levels of TLR4. How then do
neutrophils respond to LPS? The answer, in part, may lie in the
source of the LPS. Pure, protein-free LPS is a ligand for TLR4 and
CD14, but not for TLR2.41,42 However, the LPS used in most
studies of neutrophil priming is commercially prepared. Several
studies have demonstrated that commercial LPS is contaminated
with a TLR2-stimulating substance, perhaps a lipopeptide, which
can be removed by extensive phenol extraction.41,42 We therefore
examined the ability of commercial LPS (with TLR2- and TLR4-
stimulating components) and phenol-extracted LPS (TLR4 stimu-
lating only) to induce IL-8 secretion from neutrophils
and monocytes.
Commercial LPS activated neutrophils and stimulated IL-8
secretion, and this activity was enhanced by GM-CSF treatment
(Figure 9). When the TLR2-stimulating component of the LPS was
removed by phenol extraction, the resulting LPS preparation had a
substantially reduced ability to stimulate neutrophils (Figure 9). In
contrast, monocytes responded equally well to commercial unpuri-
fied and to phenol-extracted LPS (Figure 9). The receptor specific-
ity of the LPS preparations was analyzed using TLR- (and CD14)
expressing HEK293 transfected cell lines. Commercial unpurified
LPS stimulated both TLR2- and TLR4-expressing cells, while
phenol-extracted LPS stimulated TLR4-expressing cells but had no
stimulating activity for TLR2-expressing cells (Figure 9B). These
results suggest that the GM-CSF–enhanced neutrophil response to
LPS was directed to the TLR2-stimulating component(s) of the
commercial LPS preparation rather than the TLR4-stimulating
component.
GM-CSF enhances neutrophil superoxide generation
in response to TLR2-activating ligands
Neutrophils generate superoxide within minutes of stimulation.8,9
In contrast, IL-8 secretion does not reach detectable levels until
hours after stimulation. Because of the prolonged time course for
cytokine secretion, GM-CSF enhancement of IL-8 secretion could
Figure 5. LPS enhances TLR2 and CD14 but not TLR4
expression on neutrophils. Neutrophils and monocytes
were incubated with LPS or medium alone for 2 hours
prior to staining and FACS analysis. Isotype-control
Ab–stained cells are shown as gray histograms. Specific
mAb–stained cells are shown as black line histograms.
Geometric mean fluorescence intensity (SD). Neutro-
phils treated with medium alone: isotype control, 7.9
(0.4); TLR2, 12.3 (0.3); TLR4, 8.5 (0.3); and CD14, 17.5
(0.3). Neutrophils treated with LPS: isotype control, 7.9
(0.4); TLR2, 18.2 (0.4); TLR4, 8.4 (0.3); and CD14, 27.1
(0.5). Monocytes treated with medium alone: isotype
control, 12.9 (0.4); TLR2, 42.3 (0.5); TLR4, 23.5 (0.6);
and CD14, 633 (1.6). Monocytes treated with LPS:
isotype control, 12.9 (0.4); TLR2, 48.6 (0.6); TLR4, 14.8
(0.5); CD14, 566 (1.8). Significance of difference be-
tween treated cells and untreated controls: **P  .001 by
Probability Binning ChiT analysis (ChiT(X) 	 500);
P  .001 by Kolmogorov-Smirnoff analysis.
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reflect both the increase in TLR2 and CD14 expression early in the
response and further changes in gene expression during the course
of the 18 hours of incubation with TLR ligands. We therefore were
interested in studying an immediate, early response to TLR ligand
stimulation after GM-CSF induction of TLR2. We examined the
ability of TLR2 and TLR4 ligands to enhance superoxide genera-
tion from neutrophils (Figure 10). The ligands used were araLAM
(TLR2), peptidoglycan (TLR2), zymosan (TLR2), commercial
LPS (TLR2 and TLR4 ligand), or phenol-extracted LPS (TLR4
ligand). Superoxide generation was significantly increased in
GM-CSF–treated neutrophils stimulated with TLR2 ligands, that
is, zymosan, araLAM, and peptidoglycan (P  .005). Interestingly,
TLR2 ligands did not increase superoxide generation from neutro-
phils in the absence of GM-CSF treatment (Figure 10), that is, the
TLR2-specific response was highly dependent on pre-exposure
to GM-CSF.
We have also noted that GM-CSF–treated neutrophils release
very high levels of superoxide when treated with anti-TLR2
monoclonal antibody compared to cells incubated with an isotype-
matched control antibody (data not shown). The response to
anti-TLR2 treatment was dependent on pre-exposure to GM-CSF,
similar to the response to TLR2 ligands.
The TLR4-specific ligand, phenol LPS, did not significantly
increase superoxide generation from neutrophils, nor was this
response significantly increased by GM-CSF treatment of the cells
(P  .13; Figure 10). In contrast, the neutrophils responded
strongly to priming with the TLR2/TLR4 ligand containing commer-
cial (stock) LPS after GM-CSF treatment (P  .005; Figure 10).
These results suggest that the generation of superoxide from
neutrophils is preferentially primed by TLR2 ligand containing
Figure 6. Neutrophil activation by the TLR2 ligand, peptidoglycan, is enhanced
by GM-CSF treatment. (A) GM-CSF enhances peptidoglycan-stimulated IL-8
secretion from neutrophils but not from monocytes. Neutrophils and monocytes were
incubated with or without GM-CSF (1-100 U/mL) and stimulated with (E) peptidogly-
can (10 g/mL) or (f) medium alone. IL-8 secretion was measured 18 hours later by
ELISA. (B) Peptidoglycan stimulates TLR2-expressing cells. HEK293 clones express-
ing TLR2 or no TLR (none) were incubated with (f) peptidoglycan (10 g/mL), (u)
phenol-extracted LPS (10 ng/mL), or () medium alone. Secretion of IL-8 was
measured 18 hours later by ELISA.
Figure 7. Neutrophil activation by the TLR2 ligand, zymosan, is enhanced by
GM-CSF treatment. (A) GM-CSF enhances zymosan-stimulated IL-8 secretion from
neutrophils but not from monocytes. Neutrophils and monocytes were incubated with
or without GM-CSF (1-100 U/mL) and stimulated with (E) zymosan (10 g/mL) or (f)
medium alone. IL-8 secretion was measured 18 hours later by ELISA. (B) Zymosan
stimulates TLR2-expressing cells but not TLR4-expressing cells. HEK293 clones
expressing TLR2, TLR4, or no TLR (none) were incubated with (f) zymosan (10
g/mL), (u) phenol-extracted LPS (10 ng/mL), or () medium alone. Secretion of
IL-8 was measured 18 hours later by ELISA.
Figure 8. Neutrophil and monocyte activation by the TLR2 ligand, araLAM, is
enhanced by GM-CSF treatment. (A) GM-CSF enhances araLAM-stimulated IL-8
secretion from both neutrophils and monocytes. Neutrophils and monocytes were
incubated with or without GM-CSF (1-100 U/mL) and stimulated with (E) araLAM
(1 g/mL) or (f) medium alone. IL-8 secretion was measured 18 hours later by
ELISA. (B) araLAM stimulates TLR2-expressing cells but not TLR4-expressing cells.
HEK293 clones expressing TLR2, TLR4, or no TLR (none) were incubated with (f)
araLAM (1 g/mL), (u) phenol-extracted LPS (10 ng/mL), or () medium alone.
Secretion of IL-8 was measured 18 hours later by ELISA.
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microbial stimulants and that GM-CSF enhances the generation of
superoxide by TLR2 but not TLR4 ligands. Our results further
suggest that the neutrophil priming activity in LPS is primarily due
to a contaminating TLR2-stimulating activity in commercial LPS
and not to the TLR4-specific pure LPS core structure.
Discussion
The innate immune response genes of vertebrates, invertebrates,
and plants are remarkably conserved. Members of the Toll-like
receptor gene family have been identified in Drosophila, where
they are important components of antibacterial and antifungal
immunity. A family of Toll-like receptors (TLRs) has been
identified in human cells.12-14 TLR4 plays an essential role in the
ability of cells to respond to LPS.37-40 This has been demonstrated
in both mouse and human cells.37-39 A point mutation in the
C3H/HeJ TLR4 gene is responsible for the resistance of these mice
to LPS.37-39
In addition to TLR4, several other TLR proteins have been
implicated in the response to a diverse group of microbial
ligands.43,44 TLR2 has been shown to confer responsiveness to
gram-positive bacteria and their cell wall peptidoglycan.45-49 TLR2
is also an important recognition receptor for yeast cell wall
zymosan, mycobacterial araLAM, and spirochete lipopep-
tides.45-47,50-56 These observations are based on both transfection
studies and analysis of the responses of TLR2 knockout mice.49,57
Studies with knockout animals also have implicated TLR9 in the
response to bacterial CpG DNA.58
Although TLR2 was initially described as an LPS receptor, it is
now becoming apparent that TLR2 recognizes a distinct pattern of
microbial products from those recognized by TLR4.16,35,36 The
confusion over whether TLR2, TLR4, or both function as primary
LPS receptors arose because commercial preparations of LPS
contain a phenol-extractable TLR2-stimulating component, per-
haps a lipopeptide, which stimulates cells via TLR2.59-61 When this
component is removed by exhaustive phenol extraction of the LPS,
the remaining activity is directed to TLR4.41,42
The emerging picture of TLR-ligand interactions is that indi-
vidual TLR proteins recognize a set of microbial products.16,35,36
Some TLR proteins may act cooperatively in the response to
particular microbial ligands.62-64 Several studies suggest that TLR2
signals cooperatively with TLR1 or TLR6.62-64 The cooperation of
TLRs may add greater specificity or a broader range of ligand
recognition capacity to the TLR proteins as well as enhance their
signal transduction capacity.
We were interested in determining if TLRs were expressed by
neutrophils and investigating the role of TLRs in neutrophil
activation by bacterial products. The role of TLR and CD14
receptors in monocyte responses to bacteria has been well docu-
mented.16,35,36 Although neutrophils have been shown to contain
CD14 and to use this receptor in their response to LPS,21-23 the role
of TLRs in neutrophil responses remained to be established. We
have found TLR2 and CD14 expressed on normal human neutro-
phils. In contrast, TLR4 was expressed only weakly by neutrophils.
In studies of neutrophil priming, we have demonstrated that
expression of TLR2 and CD14 was up-regulated by GM-CSF or
LPS treatment. In similar studies recently published by Flo et al,65
the authors failed to detect an increase in TLR2 expression after
GM-CSF treatment, however, these authors did report that CD14
expression was increased after GM-CSF, similar to our results.65
Muzio et al19 noted an increase in TLR2 mRNA after LPS treatment
of neutrophils, similar to the increase in TLR2 expression we found
in our studies. In contrast to our studies, Muzio et al19 also detected
TLR4 mRNA expression in neutrophils. The basis for the disparity
between different studies may reflect differences in the method of
neutrophil isolation used in each study, differences in donor
Figure 10. GM-CSF enhances superoxide generation from neutrophils stimu-
lated with TLR2 ligands. Neutrophils were pretreated with (f) GM-CSF or ()
medium alone for 90 minutes and stimulated with zymosan, araLAM, peptidoglycan,
or LPS as described in “Materials and methods.” Superoxide generation was
determined by a SOD inhibitable cytochrome c reduction assay of cells incubated
with cytochrome c, f-MLP, and cytochalasin B for 15 minutes. The mean and SD of 3
replicate determinations are shown. **t test, P  .005 for comparison of untreated
versus GM-CSF–treated cells stimulated with zymosan, araLAM, peptidoglycan, or
commercial (stock) LPS (which contains a contaminating TLR2 ligand). t test, P  .13
(not significant) for comparison of untreated versus GM-CSF–treated cells stimulated
with phenol-extracted LPS (which retains TLR4-stimulating activity, but from which
the TLR2 activity has been removed).
Figure 9. Neutrophil activation by commercial LPS is enhanced by GM-CSF
treatment. (A) GM-CSF enhances commercial LPS-stimulated IL-8 secretion from
neutrophils but only weakly enhances neutrophil responsiveness to phenol-extracted
LPS. Neutrophils and monocytes were incubated with or without GM-CSF (1-100
U/mL) and stimulated with (E) commercial (stock) LPS (10 ng/mL), (F) phenol-
extracted LPS (10 ng/mL), or (f) medium alone. IL-8 secretion was measured 18
hours later by ELISA. (B) Commercial (stock) LPS stimulates both TLR2-expressing
cells and TLR4-expressing cells, but phenol-extracted LPS stimulates only TLR4-
expressing cells. HEK293 clones expressing TLR2, TLR4, or no TLR (none) were
incubated with (u) commercial (stock) LPS (10 ng/mL), (f) phenol-extracted LPS (10
ng/mL), or () medium alone. Secretion of IL-8 was measured 18 hours later
by ELISA.
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sensitivity to GM-CSF, differences in the level of TLR2 or TLR4
expression in different donors, or differences in the purity of the
cell population being analyzed.
Our GM-CSF treatment experiments were performed using a
neutrophil isolation protocol specifically developed to avoid activa-
tion of these cells during isolation.26 We found that GM-CSF
induced increases in expression of TLR2 in 3 of 4 donors in
repeated experiments. (Neutrophils from one individual were
refractory to GM-CSF induction of TLR2.) Visintin et al66 noted
that TLR1 and TLR4 levels are highly variable between donors,
with estimates of monocyte TLR4 surface expression ranging from
400 to 3200 molecules per cell, and levels of TLR1 ranging from 0
to 5400 molecules per cell. Nevertheless, our experiments are the
first to demonstrate that GM-CSF treatment dramatically enhances
the functional response of neutrophils to TLR2 ligands.
In addition to increased TLR2 and CD14 expression after
GM-CSF treatment, we have shown enhancement of the neutrophil
response to peptidoglycan, zymosan, and araLAM, microbial
ligands known to stimulate monocytes via TLR2 and CD14
receptors. That is, treatment of neutrophils with GM-CSF–
enhanced IL-8 secretion and superoxide generation in response to
TLR2 ligands. It is important to note that GM-CSF enhancement of
neutrophil responses was receptor-specific, that is, the response to
TLR2 but not TLR4 ligands was dramatically increased in GM-
CSF treatment of neutrophils.
The results of our protein expression and functional studies
suggest that GM-CSF primes for enhanced neutrophil responses to
microbial ligands in part by increasing the levels of TLR2 and
CD14 expression on the cell surface. The results further suggest
that the primary neutrophil-stimulating activity of LPS prepara-
tions is due to the contaminating TLR2-specific ligand found in
commercial LPS preparations. Removal of the TLR2-stimulating
component by phenol re-extraction significantly diminishes the
neutrophil-stimulating activity of the LPS, but does not affect the
TLR4-stimulating activity of the LPS and only slightly decreases
the monocyte-stimulating activity of the LPS. Thus, monocytes
respond strongly to the TLR4-specific, pure LPS while neutrophils
preferentially respond to the TLR2-ligand contaminated, partially
purified commercial LPS. Nevertheless, TLR4 may play a role in
neutrophil responses. Neutrophils do respond to phenol LPS (pure
TLR4 ligand) for both IL-8 secretion and superoxide generation,
albeit at lower levels than to commercial LPS. It is interesting to
note that although the neutrophil IL-8 secretion response to phenol
LPS was enhanced by GM-CSF treatment, the response to commer-
cial LPS showed a greater dose-dependence on GM-CSF treatment
than the response to phenol LPS, again suggesting that GM-CSF
preferentially enhances TLR2-dependent responses.
Our studies suggest that TLR2 expression by neutrophils
controls their response to microbial ligands and that this response is
dramatically enhanced by GM-CSF treatment. These data provide a
mechanism by which the use of GM-CSF and G-CSF enhances the
activity of neutrophils in host defense against bacterial and fungal
infection.8,67-70
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